AstraZeneca, a British pharmaceutical company, said on the 22nd local time that the supply of the new coronavirus vaccine developed jointly with Oxford University to the European Union in the first quarter will be reduced by 60% to 31 million doses due to the reduction of the output of one of the production lines in Europe, which is lower than the original estimate of about 80 million doses.
AstraZeneca, a British pharmaceutical company, will cut its initial delivery of the new crown vaccine to the European Union because its production cannot meet expectations, Xinhua reported on the 23rd.
An AstraZeneca spokesman said in a statement on the 22nd that the initial production will be lower than expected due to the decline in the production capacity of a production plant. AstraZeneca did not disclose the reason for the decline in production capacity.
The European Commission said that AstraZeneca informed the European Union on the 22nd that the vaccine delivery plan has changed and the European Union is trying to understand more details. The European Union has ordered at least 300 million doses of the new crown vaccine from AstraZeneca, and may purchase 100 million additional doses. An AstraZeneca spokesman said in a statement that it will supply tens of millions of doses of vaccine to the European Union in February and March, while increasing production capacity.
European Commission Commissioner for health and food safety, Stella & middot; kiriakidis, said on social media that EU governments were “deeply dissatisfied” with the initial delivery of the reduced vaccine and insisted that AstraZeneca clarify the delivery schedule in order to formulate vaccination plans.
The European drug administration is scheduled to decide 29 days ago whether to approve the launch of the new crown vaccine jointly developed by AstraZeneca and Oxford University. Austria, Denmark and Greece intend to pressure the agency to approve the use of AstraZeneca vaccine as soon as possible. At present, the vaccine has been authorized for emergency use in the UK.